Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

doi:10.1200/JCO.2012.47.7836

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2013

Hodi F Stephen, Corless Christopher L, Giobbie-Hurder Anita, Fletcher Jonathan A, Zhu Meijun, Marino-Enriquez Adrian, Friedlander Philip, Gonzalez Rene, Weber Jeffrey S, Gajewski Thomas F, O'Day Steven J, Kim Kevin B, Lawrence Donald, Flaherty Keith T, Luke Jason J, Collichio Frances A, Ernstoff Marc S, Heinrich Michael C, Beadling Carol, Zukotynski Katherine A, Yap Jeffrey T, Van den Abbeele Annick D, Demetri George D, Fisher David E

Abstract excerpt

PURPOSE: Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. PATIENTS AND METHODS: We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/or mutations. Patients received imatinib 400 mg once per day or 400 mg twice per day if there was no initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Imatinib Mesylate

Share to Mucous Membrane

Share to Piperazines

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-kit

Share to Sunlight

Source

Open in PubMed Open full text

Identifiers

PMID: 23775962
DOI: 10.1200/JCO.2012.47.7836
PMCID: PMC4878082

Genes

KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.PMID 23775962Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Somatic Activation of KIT in Distinct Subtypes of MelanomaSemantic proximity Read ↗

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

Sunitinib therapy for melanoma patients with KIT mutations.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.Semantic proximity Read ↗

KIT gene mutations and copy number in melanoma subtypes.Semantic proximity Read ↗

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).Semantic proximity Read ↗

Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.Semantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.